| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
ADMA Biologics Inc. (NASDAQ:ADMA) shares are trading higher Monday following the Food and Drug Administration‘s (FDA) approval of its yield enhancement process.
What To Know: ADMA's yield enhancement process has demonstrated the ability to increase production yields by approximately 20% from the same starting plasma volume.
“This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,” said Adam Grossman, President and CEO of ADMA.
Grossman added that the company is focused on advancing its internal Research and Development platform to further optimize production capabilities and develop new pipeline programs, most notably SG-001, an early-stage antibody therapy targeting S. pneumoniae.
What Else: The company is expected to report first-quarter earnings on May 12th. Analysts’ estimate earnings per share of 16 cents and revenue of $116.40 million.
Related Link: Nuvve Expands Beyond EVs With Bold Bitcoin, Crypto Investment Arm
ADMA Price Action: At the time of publication, ADMA share are trading 9.79% higher at $24.00, according to data from Benzinga Pro.
Image: via Shutterstock
Posted In: ADMA
